{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:10:33Z","timestamp":1784157033242,"version":"3.55.0"},"reference-count":63,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Understanding the pathogenesis of chronic lymphocytic leukemia (CLL) has led to the development of new prognostic and diagnostic tools, and efforts are underway to extend survival with new prognostic markers and treatment agents. This study aims to evaluate the factors affecting the prognosis and survival of patients with CLL via a retrospective study. Methods: Accordingly, the demographic features of, clinical and laboratory findings for, and hematological parameters and treatment responses of 178 CLL patients who were followed between 1 January 2015 and 31 December 2024 were analyzed before and after treatment protocols were carried out. Results: During the follow-up period, 40.8% of the patients received medical therapy, with 42.5% achieving complete remission, 49.3% experiencing partial remission, and 8.2% demonstrating no response to the treatments. The results demonstrated that an advanced Binet stage, the presence of splenomegaly, a positive direct Coombs test, the presence of a 17p deletion, thrombocytopenia, and elevated creatinine, leukocyte, and lymphocyte counts were associated with increased mortality. Elevated Binet and Rai stages, the existence of 17p deletion, and reduced hemoglobin levels were identified as statistically significant factors. Conclusions: Given the unfavorable prognosis of CLL patients exhibiting a positive direct Coombs test and compromised renal function, further investigations are required to validate the necessity of more rigorous monitoring and, possibly, early intervention. These findings underscore the importance of identifying high-risk factors in CLL to optimize patient management and improve long-term outcomes.<\/jats:p>","DOI":"10.3390\/diagnostics15060728","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:02:16Z","timestamp":1741935736000},"page":"728","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Lymphocytic Leukemia: Investigation of Survival and Prognostic Factors with Drug-Related Remission"],"prefix":"10.3390","volume":"15","author":[{"given":"G\u00f6khan","family":"Pekta\u015f","sequence":"first","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, 48000 Mu\u011fla, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercan","family":"G\u00f6n\u00fcl","sequence":"additional","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, 48000 Mu\u011fla, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeyma","family":"\u00d6nc\u00fc","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Becit K\u0131z\u0131lkaya","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Faculty of Pharmacy, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6khan","family":"Sadi","sequence":"additional","affiliation":[{"name":"Department of Biology, K.O. Science Faculty, Karamanoglu Mehmetbey University, 70100 Karaman, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0055-7688","authenticated-orcid":false,"given":"Mehmet Bilgehan","family":"Pekta\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03200 Afyonkarahisar, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a035220","DOI":"10.1101\/cshperspect.a035220","article-title":"Chronic Lymphocytic Leukemia","volume":"11","author":"Chiorazzi","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Urso, A., Cavazzini, F., Ballardini, M.P., Gambara, S., Consolo, S., Rigolin, G.M., and Cuneo, A. (2023). First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era. Cancers, 15.","DOI":"10.20944\/preprints202306.1898.v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41375-020-01057-5","article-title":"Ethnic and Geographic Diversity of Chronic Lymphocytic Leukaemia","volume":"35","author":"Yang","year":"2021","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with High-Dose Dexamethasone (HD-DXM) in Previously Untreated Patients Affected by Idiopathic Thrombocytopenic Purpura: A GIMEMA Experience","volume":"109","author":"Mazzucconi","year":"2007","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/oemed-2014-102654","article-title":"Soft Tissue Sarcoma, Non-Hodgkin\u2019s Lymphoma and Chronic Lymphocytic Leukaemia in Workers Exposed to Phenoxy Herbicides: Extended Follow-up of a UK Cohort","volume":"72","author":"Coggon","year":"2015","journal-title":"Occup. Environ. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/ijlh.13170","article-title":"Flow Cytometry in the Diagnosis of Mature B-cell Lymphoproliferative Disorders","volume":"42","author":"Debord","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"HemaSphere"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) Mutation Status, CD38 Expression Level, Genomic Aberrations, and Survival in Chronic Lymphocytic Leukemia","volume":"100","author":"Seiler","year":"2002","journal-title":"Blood"},{"key":"ref_11","first-page":"185","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11899-015-0294-x","article-title":"Prognostic Factors for Chronic Lymphocytic Leukemia","volume":"11","author":"Chen","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic Lymphocytic Leukaemia","volume":"104","author":"Ferreri","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical Staging of Chronic Lymphocytic Leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic Lymphocytic Leukemia: 2022 Update on Diagnostic and Therapeutic Procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A New Prognostic Classification of Chronic Lymphocytic Leukemia Derived from a Multivariate Survival Analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yun, X., Zhang, Y., and Wang, X. (2020). Recent Progress of Prognostic Biomarkers and Risk Scoring Systems in Chronic Lymphocytic Leukemia. Biomark. Res., 8.","DOI":"10.1186\/s40364-020-00222-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41375-020-0727-y","article-title":"Prognostic Model for Newly Diagnosed CLL Patients in Binet Stage A: Results of the Multicenter, Prospective CLL1 Trial of the German CLL Study Group","volume":"34","author":"Hoechstetter","year":"2020","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00277-021-04600-1","article-title":"Survival Trends in Chronic Lymphocytic Leukemia across Treatment Eras: US SEER Database Analysis (1985\u20132017)","volume":"100","author":"Alrawashdh","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/s41375-019-0630-6","article-title":"Influence of Obesity and Gender on Treatment Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) Undergoing Rituximab-Based Chemoimmunotherapy","volume":"34","author":"Hopfinger","year":"2020","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.leukres.2009.06.013","article-title":"High Incidence of Chronic Lymphocytic Leukemia (CLL) Diagnosed by Immunophenotyping: A Population-Based Canadian Cohort","volume":"33","author":"Seftel","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/aam.aam_60_19","article-title":"Demographic Pattern of Chronic Lymphocytic Leukemia in a Tertiary Hospital in Calabar, South-South Nigeria","volume":"19","author":"Akaba","year":"2020","journal-title":"Ann. Afr. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3324\/haematol.2013.101378","article-title":"The Clinical Significance of Patients\u2019 Sex in Chronic Lymphocytic Leukemia","volume":"99","author":"Catovsky","year":"2014","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"106538","DOI":"10.1016\/j.leukres.2021.106538","article-title":"Impact of Age and Treatment Institution Type on Outcomes of Patients Treated for Chronic Lymphocytic Leukemia in British Columbia, Canada","volume":"103","author":"Huang","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/10428194.2019.1680840","article-title":"Survival Improvement of Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Care 1995\u20132017","volume":"61","author":"Weide","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.31557\/apjcc.2022.7.3.467-474","article-title":"Characteristics of Chronic Lymphocytic Leukemia in Sudanese Patients","volume":"7","author":"Basabaeen","year":"2022","journal-title":"Asian Pac. J. Cancer Care"},{"key":"ref_27","unstructured":"Naeim, F., Rao, P.N., and Grody, W.W. (2008). Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches, Academic Press Inc.. [1st ed.]."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2008.05.003","article-title":"Prognostic Markers in Chronic Lymphocytic Leukemia: A Comprehensive Review","volume":"23","author":"Verhasselt","year":"2009","journal-title":"Blood Rev."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Basabaeen, A.A., Abdelgader, E.A., Babekir, E.A., Eltayeb, N.H., Altayeb, O.A., Fadul, E.A., Bahashwan, O.S., and Ibrahim, I.K. (2019). Clinical Presentation and Hematological Profile among Young and Old Chronic Lymphocytic Leukemia Patients in Sudan. BMC Res. Notes, 12.","DOI":"10.1186\/s13104-019-4239-7"},{"key":"ref_30","first-page":"197","article-title":"Clinical Presentation and Outcome of Thai Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of 184 Cases","volume":"23","author":"Sriphatphiriyakun","year":"2005","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_31","first-page":"187","article-title":"Chronic Lymphocytic Leukaemia: A-Twenty-Years Experience and Problems in Ile-Ife, South-Western Nigeria","volume":"10","author":"Salawu","year":"2010","journal-title":"Afr. Health Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Puiggros, A., Blanco, G., and Espinet, B. (2014). Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/435983"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/gcc.22650","article-title":"Mutational and Cytogenetic Analyses of 188 CLL Patients with Trisomy 12: A Retrospective Study from the French Innovative Leukemia Organization (FILO) Working Group","volume":"57","author":"Chevret","year":"2018","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.3324\/haematol.2018.190132","article-title":"Trisomy 12 Chronic Lymphocytic Leukemia Expresses a Unique Set of Activated and Targetable Pathways","volume":"103","author":"Abruzzo","year":"2018","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaoncol.2015.0779","article-title":"Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era","volume":"1","author":"Nabhan","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clml.2015.02.001","article-title":"Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients with Trisomy 12 Chronic Lymphocytic Leukemia","volume":"15","author":"Strati","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","article-title":"Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation","volume":"23","author":"Yu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 Mutation and Survival in Chronic Lymphocyticleukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"v814","DOI":"10.1093\/annonc\/mdz269.055","article-title":"Incidence and Outcome of Chronic Lymphocytic Leukemia with Deletion 17p: An Indian Experience; Challenges and Opportunities","volume":"30","author":"Gogia","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00277-024-05627-w","article-title":"Conditional Survival to Assess Prognosis in Patients with Chronic Lymphocytic Leukemia","volume":"103","author":"Schlosser","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3324\/haematol.2021.280376","article-title":"A Clinical Practice Comparison of Patients with Chronic Lymphocytic Leukemia with and without Deletion 17p Receiving First-Line Treatment with Ibrutinib","volume":"107","author":"Mato","year":"2022","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients with Chronic Lymphocytic Leukemia: Results from the US Intergroup Phase III Trial E2997","volume":"25","author":"Grever","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.37489\/2588-0519-2022-3-31-34","article-title":"Chronic Lymphocytic Leukemia Prediction Using Data Mining Methods","volume":"3","author":"Markovtseva","year":"2022","journal-title":"Kachestvennaya Klin. Prakt. = Good Clin. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1200\/JCO.2022.40.16_suppl.7544","article-title":"Survival Outcomes in Patients with Chronic Lymphocytic Leukemia Treated at Academic Centers","volume":"40","author":"Vardell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_46","unstructured":"(2025, February 01). Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic Lymphocytic Leukemia in the Elderly: Clinico-Biological Features, Outcomes, and Proposal of a Prognostic Model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clml.2018.06.023","article-title":"Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance over the Course of the Disease and Are Surrogates for Response to Therapy","volume":"18","author":"Vicente","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1590\/S1516-31802000000400002","article-title":"Prognosis Related to Staging Systems for Chronic Lymphocytic Leukemia","volume":"118","author":"Faria","year":"2000","journal-title":"Sao Paulo Med. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.7314\/APJCP.2012.13.7.3009","article-title":"Chronic Lymphocytic Leukemia and Prognostic Factors","volume":"13","author":"Mozaheb","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.15397","article-title":"Changes in Clinical Stage Identify Patients with CLL and Different Outcome within IwCLL Partial Response: RESONATE Study","volume":"185","author":"Moreno","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/CMAR.S17470","article-title":"Fo\u00e0 Clinical Relevance and Treatment of Nonautoimmune Anemia in Chronic Lymphocytic Leukemia","volume":"3","author":"Molica","year":"2011","journal-title":"Cancer Manag. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/10428190290026295","article-title":"The Development of Marked Elevation in White Blood Cell Count Does Not Predict Inferior Outcome in Chronic Lymphocytic Leukemia","volume":"43","author":"Silverman","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood.V122.21.5302.5302","article-title":"Renal Disease in Patients with Chronic Lymphocytic Leukemia (CLL)","volume":"122","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal Complications in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis: The Mayo Clinic Experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/S2152-2650(22)01329-5","article-title":"CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients With Treatment-Na\u00efve (TN) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"22","author":"Kahl","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.seminhematol.2010.01.005","article-title":"Rituximab in Chronic Lymphocytic Leukemia","volume":"47","author":"Jaglowski","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_58","first-page":"2827","article-title":"Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-World Analysis by Age from a German Registry and Review of the Literature","volume":"36","author":"Kleeberg","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I Treat CLL Patients with Ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.7314\/APJCP.2015.16.14.6007","article-title":"Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: A Marker of Advanced Clinical Disease","volume":"16","author":"Abbas","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/JBM.S296225","article-title":"Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review","volume":"12","author":"Ahmed","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/10428190903111930","article-title":"The Negative Prognostic Significance of Positive Direct Antiglobulin Test in Chinese Patients with Chronic Lymphocytic Leukemia","volume":"50","author":"Xu","year":"2009","journal-title":"Leuk. Lymphoma"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/6\/728\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:53:39Z","timestamp":1760028819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/6\/728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":63,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["diagnostics15060728"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15060728","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}